SEC Form 4 · accession 0000899243-19-004939
MELINTA THERAPEUTICS, INC. /NEW/ · MLNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Johnson
Officer — Chief Executive Officer · Director
Period of report
Feb 22, 2019
Accepted (ET)
Feb 26, 2019 · 9:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001461993
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | $0.00 | Feb 22, 2019 | A | 400,000 | A | — | — | Common Stock | 400,000 | 400,000 | D |
Explanation of responses
- F1The restricted stock units will vest in equal quarterly installments over the two year period following February 22, 2019, subject to Mr. Johnson's continued service with the Issuer through the applicable vesting date.
Remarks
All share numbers in this Form 4 reflect the 1-for-5 reverse stock split which became effective as of 5 p.m. February 21, 2019.